All In Biotech

Drug Trial Radar · NCT06075030

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Cancer-Related Anemia Patients Receiving Chemotherapy

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Dec 2027

Primary completion

Dec 2027

Study completion May 2028

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

Conditions

  • Chemotherapy Induced Anemia

Interventions

  • AND017Drug

    Oral administration of AND017 capsules three times per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of responding patientTime frame: From baseline to Week 6 or End of Treatment visit

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.